Longevity & Energy · Investigational · clinical-stage
SS-31
Elamipretide · mitochondrial peptide · Longevity · Energy · Performance
A clinical-stage mitochondrial peptide, studied for cellular energy architecture.
- Form
- 50 mg — pre-reconstituted in the Cellvéra injector
- Oversight
- Licensed clinician, included
- Price
- From R6 500 / protocol
Opens a private email to our concierge · nothing is charged
Checkout begins your confidential medical intake. SS-31 is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.
Pathway
A four-amino-acid peptide, also known as elamipretide, developed by Stealth BioTherapeutics — the most clinically serious compound in the mitochondrial class, with completed Phase 2 and Phase 3 programmes across several rare diseases.
Mechanism
Designed to cross into cells and concentrate in the inner mitochondrial membrane, where it binds cardiolipin — the lipid that holds the folded structure of the mitochondrion together. Stabilising it supports efficient energy production and reduces leakage of damaging free radicals: repairing the architecture rather than adding fuel.
Studied for
- Barth syndrome and primary mitochondrial myopathy
- Dry age-related macular degeneration
- Heart failure and cardiac ischaemia
- Cellular energy and age-related mitochondrial decline
Areas of research interest — not promised outcomes.
Where the evidence stands
A genuine clinical-stage drug with Phase 2 and Phase 3 trials completed across several rare diseases — results have been mixed, with encouraging signals alongside missed primary endpoints. Regulatory review activity has centred on Barth syndrome.
Typical protocol
Dosing is individualised and set by your supervising clinician at intake. Published human dosing for this compound is not established; conservative titration and monitoring are part of every protocol.
Contraindications & cautions
Investigational use only — regulatory status still evolving. Not a general-wellness product; its evidence base concerns specific rare conditions. Pregnancy or breastfeeding.
Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.